ECE2017 Eposter Presentations: Interdisciplinary Endocrinology Pituitary - Basic (1 abstracts)
Non-functioning pituitary adenomas: association between clinical-pathological and molecular parameters
Ana Barrera-Martín 1 , María-Carmen Vázquez-Borrego 2 , Ángel Rebollo-Román 1 , Pedro-Blas García-Jurado 3 , Paloma Moreno-Moreno 1 , María-Rosa Alhambra-Expósito 1 , Álvaro Toledano-Delgado 4 , Justo-P Castaño 2 , María-Ángeles Galvez-Moreno 1 & Raúl-M Luque 2
1Endocrinology Service, Hospital Universitario Reina Sofia, Córdoba, Spain; 2IMIBIC/HURS, Department of Cell Biology, Physiology and Immunology, University of Cordoba; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn); Campus de Excelencia Internacional Agroalimentari, Córdoba, Spain; 3Radiology Service. Hospital Universitario Reina Sofia, Córdoba, Spain; 4Neurosurgery Service. Hospital Universitario Reina Sofia, Córdoba, Spain.
Non-functioning pituitary-adenomas (NFPAs) represent the most common pituitary tumor-type. To date, there are not clinical, biochemical, anatomo-pathological, immuno-histochemical or molecular parameters useful to predict their remission. Therefore, the aim of this study was to evaluate the potential relationship between the clinical, biochemical and pathological characteristics of patients with NFPAs, the expression profile of these tumours and the clinical outcomes during their follow-up. An observational/retrospective-study of patients with NFPAs evaluated between January 2002-December 2015 was implemented at our hospital, by collecting a complete set of clinical/biochemical/radiological-data from patients (n=34; 50% women; age: 56.2±11.9 years-old), and anatomopathological and molecular (26 genes measured by qPCR) data from the tumours. Mean follow-up of patients: 5.2±3.9 years. Symptomatology: 38.2% campimetric alterations, 35.3% headache and 11.8% symptoms derived from hormonal deficits. A predominant expression of Dopamine-receptor 2 (DRD2) followed by somatostatin-receptors (sst) 3 and 2 was found. Furthermore, a consistent increase in the expression of the majority of receptors analyzed between first and second surgery of the patients was observed. Interestingly, lower expression-levels of sst1 and sst3 were found in patients pre-treated with statins. Correlations between receptors and/or molecular markers (i.e. DRD2 with AVPR1b, sst5TMD5 with serum testosterone-levels or sst5TMD4 with p53-levels) were observed. Additionally, male sex, lower levels of pre-surgery cortisol and testosterone and low sst5, AVPR1b and PTTG1 expression were associated with a higher curation of patients. Although further studies with a larger cohort of well-characterized patients are needed, our molecular and clinical data suggest that a putative pharmacological treatment for this pathology might be somatostatin-analogues with affinity for sst3 or dopamine agonists (e.g. pasireotide or cabergoline), that statin-treatment might influence the expression levels of some sst-subtypes (e.g. sst3), and that some clinical/molecular markers (i.e. sex, pre-surgery cortisol and testosterone levels and sst5/AVPR1b/PTTG1-expression) could be associated with the curation of patients with NFPAs.
Volume 49
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more